Literature DB >> 16391708

Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy.

Mario Fritsch Neves1, Farhad Amiri, Agostino Virdis, Quy N Diep, Ernesto L Schiffrin.   

Abstract

Activation of the renin-angiotensin-aldosterone system is associated with increased extracellular matrix and inflammatory markers in the cardiovascular system. We evaluated the effects of aldosterone antagonism on cardiovascular structure, collagen deposition, and expression of inflammatory markers in 2-week angiotensin (Ang) II-infused rats (120 ng.kg-1.min-1, s.c.)+/-spironolactone or hydralazine (25 mg.kg-1.d-1). Aortic and cardiac collagen density was evaluated with Sirius red staining. NFkappaB and AP-1 were measured by a electrophoretic mobility shift assay, and ED-1 (macrophage marker) and vascular cell adhesion molecule-1 (VCAM-1) were measured by immunohistochemistry. Ang II increased blood pressure (176+/-2 mmHg vs. 115+/-1 mmHg in controls, p<0.01), which was attenuated by spironolactone (147+/-4 mmHg, p<0.01) and prevented by hydralazine (124+/-2 mmHg, p<0.01). Ang II enhanced left ventricular interstitial collagen type I/III deposition (4.1%+/-0.1% vs. 3.1%+/-0.2%, p<0.05), and this was attenuated by spironolactone but not hydralazine. Ang II-induced cardiac perivascular fibrosis was prevented by spironolactone and hydralazine. Ang II significantly increased cardiac AP-1 activity and ED-1 expression, which was prevented by spironolactone only. Ang II-enhanced NFkappaB activity, and VCAM-1 expression was reduced by spironolactone and hydralazine, whereas aortic hypertrophy was prevented by spironolactone and slightly reduced by hydralazine. In conclusion, blockade of mineralocorticoid receptors with spironolactone inhibited Ang II-induced aortic hypertrophy, cardiac transcription factor activation, upregulation of downstream inflammatory markers, and collagen deposition, thus preventing Ang II-induced cardiovascular damage.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16391708     DOI: 10.1139/y05-068

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  25 in total

Review 1.  Impact of aldosterone antagonists on the substrate for atrial fibrillation: aldosterone promotes oxidative stress and atrial structural/electrical remodeling.

Authors:  Fadia Mayyas; Karem H Alzoubi; David R Van Wagoner
Journal:  Int J Cardiol       Date:  2013-08-15       Impact factor: 4.164

2.  Novel molecular mechanisms in the inhibition of adrenal aldosterone synthesis: Action of tolvaptan via vasopressin V2 receptor-independent pathway.

Authors:  Yusuf Ali; Kaoru Dohi; Ryuji Okamoto; Kan Katayama; Masaaki Ito
Journal:  Br J Pharmacol       Date:  2019-04-07       Impact factor: 8.739

3.  Larger ascending aorta in primary aldosteronism: a 3-year prospective evaluation of adrenalectomy vs. medical treatment.

Authors:  Guido Zavatta; Guido Di Dalmazi; Carmine Pizzi; Giovanni Bracchetti; Cristina Mosconi; Caterina Balacchi; Uberto Pagotto; Valentina Vicennati
Journal:  Endocrine       Date:  2018-11-14       Impact factor: 3.633

4.  Mineralocorticoid receptor blocker eplerenone reduces pain behaviors in vivo and decreases excitability in small-diameter sensory neurons from local inflamed dorsal root ganglia in vitro.

Authors:  Fei Dong; Wenrui Xie; Judith A Strong; Jun-Ming Zhang
Journal:  Anesthesiology       Date:  2012-11       Impact factor: 7.892

Review 5.  Aldosterone and inflammation.

Authors:  Kimberly C Gilbert; Nancy J Brown
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2010-06       Impact factor: 3.243

6.  Blocking the mineralocorticoid receptor improves effectiveness of steroid treatment for low back pain in rats.

Authors:  Ling Ye; Wenrui Xie; Judith A Strong; Jun-Ming Zhang
Journal:  Anesthesiology       Date:  2014-09       Impact factor: 7.892

7.  Aldosterone activates NF-kappaB in the collecting duct.

Authors:  Valérie Leroy; Sophie De Seigneux; Victor Agassiz; Udo Hasler; Marie-Edith Rafestin-Oblin; Manlio Vinciguerra; Pierre-Yves Martin; Eric Féraille
Journal:  J Am Soc Nephrol       Date:  2008-11-05       Impact factor: 10.121

8.  Autocrine and paracrine function of Angiotensin 1-7 in tissue repair during hypertension.

Authors:  Weixin Meng; Wenyuan Zhao; Tieqiang Zhao; Chang Liu; Yuanjian Chen; Hongyu Liu; Yao Sun
Journal:  Am J Hypertens       Date:  2014-01-15       Impact factor: 2.689

9.  Aldosterone activates endothelial exocytosis.

Authors:  Youngtae Jeong; Damian F Chaupin; Kenji Matsushita; Munekazu Yamakuchi; Scott J Cameron; Craig N Morrell; Charles J Lowenstein
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-17       Impact factor: 11.205

10.  Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt.

Authors:  William B Lea; Eun Soo Kwak; James M Luther; Susan M Fowler; Zuofei Wang; Ji Ma; Agnes B Fogo; Nancy J Brown
Journal:  Kidney Int       Date:  2009-02-18       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.